Cabergoline: Dopamine Agonist and Prolactin Research

Research Disclaimer: Cabergoline is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Cabergoline (trade name: Dostinex; Pfizer) is an ergot-derived D2 dopamine receptor agonist with high selectivity and long duration of action. Clinically approved for hyperprolactinemia and Parkinson's disease, cabergoline is used in androgen research primarily when 19-nor steroids (nandrolone, trenbolone) are part of the protocol — both produce prolactin elevation via their progestogenic (PR agonist) activity, which can suppress dopamine tone at the tuberoinfundibular dopaminergic (TIDA) pathway that normally inhibits prolactin secretion.

Table of Contents#

1. Prolactin Regulation: The Dopamine Connection
2. 19-Nor Steroids and Prolactin Elevation
3. Cabergoline Mechanism: D2 Agonism at Lactotrophs
4. Pharmacokinetics: Long t½
5. Research Applications
6. Protocols
7. Key References

Prolactin Regulation: The Dopamine Connection#

Prolactin (PRL) is secreted from anterior pituitary lactotroph cells:

• Primary regulatory mechanism: tonic dopaminergic inhibition
• Tuberoinfundibular dopaminergic (TIDA) neurons in the hypothalamus → dopamine → portal blood → pituitary lactotroph D2 receptors → inhibits prolactin synthesis and secretion
• Dopamine is the dominant prolactin-inhibiting factor (PIF)

Normal prolactin levels (rat, serum):

• Male: ~5–15 ng/mL
• Female: ~15–30 ng/mL (higher, cycling)
• Post-suckling: pulse to 200+ ng/mL

Prolactin regulation beyond dopamine:

• TRH (thyrotropin-releasing hormone): prolactin stimulator
• VIP (vasoactive intestinal peptide): minor stimulator
• Estrogen: increases pituitary lactotroph sensitivity to TRH → elevated E2 → higher baseline prolactin → relevant in high-dose testosterone protocols where aromatization is high

19-Nor Steroids and Prolactin Elevation#

19-Nor anabolic steroids — nandrolone, trenbolone — are potent PR agonists (progesterone receptor):

• Nandrolone PR RBA: ~20% progesterone
• Trenbolone PR RBA: ~80–100% progesterone

The PR agonism pathway to prolactin:

1. PR activation in the hypothalamus → reduces dopamine synthesis/release from TIDA neurons
2. Less dopamine reaches lactotroph D2 receptors → dopaminergic inhibition of prolactin decreases
3. Lactotrophs release more prolactin
4. Result: hyperprolactinemia at high doses of 19-nor compounds

Prolactin elevation is dose-dependent:

• Moderate 19-nor doses → modest prolactin rise (~20–50% above baseline)
• High-dose trenbolone: prolactin can reach 2–5× baseline
• Combined 19-nor compounds (trenbolone + nandrolone): additive PR → additive prolactin elevation

Cabergoline Mechanism: D2 Agonism at Lactotrophs#

Cabergoline acts directly on pituitary lactotroph D2 receptors (bypassing the TIDA pathway):

• D2 receptor agonism → Gi protein → decreases cAMP → decreased prolactin synthesis and secretion
• Also acts on hypothalamic TIDA pathway D2 autoreceptors: increases dopaminergic tone
• Net: potent, sustained prolactin suppression

Selectivity:

• Cabergoline has highest affinity for D2 > D3 > D4 > D1
• Very low affinity for 5-HT receptors at research doses
• Limited cardiac valvulopathy risk compared to older ergot agonists (pergolide) — the cardiac concern is with very high Parkinson's doses; at standard prolactin-suppression doses, cabergoline is well-tolerated

Pharmacokinetics: Long t½#

Rat PK:

• t½ shorter: ~10–15h
• Dosing: 2–3× per week adequate for sustained prolactin suppression

Research Applications#

1. Prolactin measurement as 19-nor proxy#

In multi-compound protocols involving nandrolone or trenbolone:

• Baseline + weekly serum prolactin → tracks 19-nor PR agonism indirectly
• Cabergoline group: co-administer 0.025–0.1 mg/kg twice weekly → confirms that elevated prolactin is dopamine-suppressible → pharmacologically attributable to 19-nor PR agonism (not other pathways)

2. Isolating prolactin contributions to HPTA#

Prolactin at high levels suppresses GnRH:

• Hyperprolactinemia → directly suppresses GnRH pulse frequency
• In 19-nor research: HPTA suppression has 3 components: AR, PR, and prolactin-mediated
• Cabergoline suppresses only the prolactin component → allows attribution analysis

3. Sexual function research#

High prolactin → suppresses libido and sexual behavior in animal models:

• Cabergoline rescues prolactin-induced sexual dysfunction → used to study prolactin's role in post-ejaculatory refractory period and dopamine-prolactin axis in sexual motivation

Protocols#

Prolactin suppression in nandrolone-treated rats#

Receptor binding assay (D2 vs. D1 selectivity)#

Key References#

1. Biller BMK, et al. (1996). "Once weekly cabergoline versus twice weekly bromocriptine in hyperprolactinemia." Journal of Clinical Endocrinology and Metabolism, 81(7):2338–2343.

2. Verhelst J, et al. (1999). "Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients." Journal of Clinical Endocrinology and Metabolism, 84(7):2518–2522.

3. Bhasin S & Buckwalter JG. (2001). "Testosterone supplementation in older men." Journal of Andrology, 22(5):718–731.

Research Use Only: Cabergoline is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science